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Abstract
Purpose Little scientific evidence on blood loss and transfu-
sion rates after short-stem hip arthroplasty exists. The hypoth-
esis of this study was that the blood loss and transfusion rate is
lower in short stems compared to straight stems.
Methods We compared 124 patients who underwent total hip
arthroplasty (THA) using a short-stem design (group 1) and
141 patients using a straight-stem design (group 2). All pa-
tients were operated on by the same surgeon, and both groups
were similar in age, gender, affected side, body mass index,
and ASA score.
Results The calculated blood loss was 1139 ml in group 1 and
1358 ml in group 2 (p < 0.001). The transfusion rate was 8% in
group 1 and 15.6% in group 2 (p < 0.001). There was no sig-
nificant difference between groups 1 and 2 regarding compli-
cations and operation time (p > 0.05).
Conclusion Compared to patients after straight stem THA,
both blood loss and blood transfusion rates were lower in
patients after short stem THA.
Keywords Blood loss . Hip arthroplasty . Short stem .
Straight stem . Transfusion rate
Introduction
Undoubtedly, total hip arthroplasty (THA) is one of the most
successful surgeries of the past century in orthopaedic surgery.
THA provides good long-term outcomes and high satisfaction
rates in a great number of patients [1, 2]. Over the past few
decades, a commonly used femoral component in THA has
become the straight tapered titanium alloy stem with a rectan-
gular cross-section. Despite good results, there are also some
disadvantages, such as bone remodeling due to stress
shielding and non-ideal load transformation [3, 4].
Additionally, straight designs often do not allow true minimal-
ly invasive implantation, causing some degree of muscle and
soft tissue damage.
In the past few years, the use of femoral short-stems has
been on the rise. Short-stem designs are assumed to have
several advantages over straight stems. Due to the short length
of the stem and a reduced lateral shoulder, more native bone is
preserved, which is very important, especially in younger pa-
tients [4, 5]. Shorter stems facilitate implantation and can be
gently implanted, without harming most soft tissue. The esti-
mated lower tissue trauma also may reduce blood loss and
transfusion rates.
The estimated blood loss after THA is reported to be up to
1800 ml [6–8], with transfusion rates up to 69% [9, 10].
Post-operative anemia can lead to hypertension, tachycardia,
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myocardial infarction [11, 12]. Blood transfusions after THA
are common, but not without risks for the patient [13, 14].
Therefore, efforts should be made to reduce blood loss in
THA, and keep the transfusion rate as low as possible, to
avoid potentially serious complications for the patient and to
help minimize healthcare system costs.
We therefore set out a study to compare blood loss and
transfusion rates in THA using straight-stem and short-stem
designs.We hypothesized that blood loss and transfusion rates
are lower in patients after short-stem hip arthroplasty.
Materials and methods
Institutional review board approval was obtained for this
study. In this retrospective comparative study, we reviewed
124 patients who underwent THA using a short-stem design
(group 1) and 141 patients using a straight-stem design (group
2). In all group 1 patients, a cement-less, short-stem (Optimys,
Mathys, Bettlach, Switzerland) was implanted, and in all
group 2 patients, a cement-less, straight-stem (Alloclassic
Zweymüller, Zimmer GmbH, Winterthur, Switzerland) was
used. For the acetabulum component, a cement-less press-fit
cup (RM Pressfit Vitamys, Mathys, Bettlach, Switzerland)
was used for patients in group 1, and a self-tapping screw
cup (Alloclassic Variall shell, Zimmer GmbH, Winterthur,
Switzerland) was used for patients in group 2.
For all patients in group 1, an anterolateral approach and
for all patients in group 2 an lateral approach was used.
Patients in groups 1 and 2 were similar according to age,
gender, affected side, body mass index, and ASA score.
Patient data details for both groups are shown in Table 1.
All patients in groups 1 and 2 were operated on during the
time period from 06/2013 to 06/2015 and from 01/2010 to 12/
2011, respectively. Time periods for recruiting patients in
groups 1 and 2 were chosen randomly.
All data for this study were obtained from a prospective
gathered database.
Pre-operative planning for all hips was carried out based on
analogue or digital X-ray templates. All surgeries were per-
formed by one, highly experienced surgeon.
All patients had primary osteoarthritis and no previous sur-
geries of the affected hip.
Patients with coagulation disorder, liver or kidney disease
ormalignant tumors, previous surgeries of the affected hip and
any other indications for THA, except primary arthritis, were
excluded from this study.
No strategies to reduce blood loss, such as cell savers, or
pharmacological agents were used. In all patients, in both
groups, 1 intra articular suction drain was administered and
removed on the first post-operative day. During surgery,
monopolar cautery was used for haemostasis in all patients.
Blood transfusions were administered in patients with
haemoglobin levels less than 7 g/dL and haemodynamic symp-
toms such as hypotension, shortness of breath or fatigue that did
not respond to fluid administration.
Low-molecular weight heparin (LMWH, 40 mg once daily)
or Rivaroxaban (10 mg orally once daily) was used to prevent
deep vein thrombosis. Pre-operatively, haemoglobin and
haematocrit levels were obtainedwithin one week before surgery
for all patients. Post-operatively, haemoglobin and haematocrit
values were obtained on the first post-operative day (day 1) and
on the third post-operative day (day 3).
The blood volume was calculated using Moore’s formula.
Blood loss was calculated using haematocrit levels with the
formula of Bourke [15]. Total blood transfusions were record-
ed for each patient.
Statistical methods
Data consistency was checked and data were screened for out-
liers and normality by using quantile plots.
Crosstabulation tables with Fisher’s Exact test or Pearson’s
test were used to analyze the crosstabulations.
A repeated ANOVA and paired and two-sided Student t-tests
as post-hoc tests were used to compare Hb and HcT values
among the different groups. A generalized model based on the
Poisson distribution was used to compare the number of trans-
fusions. All reported tests were two-sided, and p-values <0.05
were considered significant. All statistical analyses in this report
were performed by use of STATISTICA 13 (Hill, T. & Lewicki,
P. Statistics: Methods and Applications. StatSoft, Tulsa, OK).
Results
The mean pre-operative haemoglobin levels did not significantly
differ between groups 1 and 2 (14.1, 13.8, p= 0.11). The mean
pre-operative haematocrit also did not differ significantly be-
tween group 1 and group 2 (42.1, 41.1 p = 0.16). In both groups,
age, gender, side of extremity, bodymass index, and ASA scores
were similar and did not significantly differ (Table 1).
Table 1 Demographic data of patients in both groups. f=female,
m=male, r=right, l=left, BMI=Body-mass-index, ASA=American
Society of Anesthesiologists Classification
Short-stem Straight-stem p value
Gender (f/m) 81/43 92/49 0.98
Age 69.1 68.2 0.58
Side (l/r) 54/70 66/75 0.57
BMI 27.3 27.2 0.90
ASA I/II/III 21/86/17 33/94/14 0.32
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In group 1 and group 2, 19.4% (24/124) and 27.7% (39/
141) of patients received Rivaroxaban, and 80.6% (100/124)
and 72.3% (102/141) of patients received low molecular
weight heparin (LMWH), as thrombosis prevention, respec-
tively. The type of deep vein thrombosis prophylaxis did not
significantly differ between the groups (p = 0.11).
The post-operative haemoglobin and haematocrit on the first
post-operative day (day 1) did not significantly differ between
the groups. On the third post-operative day (day 3), the
haematocrit and haemoglobin levels in group 2 were signifi-
cantly lower (p < 0.001) (Tables 2, 3 and Figs. 1, 2).
The calculated blood loss was 1139 ml in group 1 and
1358 ml in group 2 (p < 0.001). The calculated blood loss
for patients in group 1 treated with LMWH and
Rivaroxaban did not differ significantly (1130 ml vs
1180 ml, p = 0.6325). The calculated blood loss for patients
in group 2 treated with LMWHand Rivaroxaban did not differ
significantly (1371 ml vs 1325 ml, p = 0.6246). Patients treat-
ed with LMWH in group 1 show significantly lower blood
loss than patients in group 2 (1130ml vs 1371ml, p = 0.0002).
Blood loss in patients treated with Rivaroxaban in both groups
did not differ significantly (1180 ml vs 1326 ml, p = 0.2982).
The calculated blood loss for patients in group 1 treated with
LMWH is significantly lower than for patients in group 2
treated with Rivaroxaban (1130 ml vs 1325 ml, p = 0.0193).
The calculated blood loss for patients treated with
Rivaroxaban in group 1 was significantly lower than patients
treated with LMWH in group 2 (1180 ml vs 1371 ml,
p = 0.2981). Figure 3 show blood loss for both groups accord-
ing to thrombosis prophylaxis.
The transfusion rate was 8% (10 patients) in group 1, and
15.6% (22 patients) in group 2 (p < 0.001). In group 2, the
mean number of transfused packs per patient of red cell trans-
fusions was 2.2 (48/22), and in group 1, was 1.3 (13/10,
p < 0.05).
Compared to group 2, the mean transferred pack of red cell
transfusions was significantly lower in group 1 (0.1, 0.34,
p < 0.001). Table 4 shows calculated blood loss and transfu-
sions in detail.
There was no significant difference between groups 1 and
2, regarding complications (p= 0.532). Mean operation timewas
63 minutes (range, 45–91) in group 1 and 68 min (range, 49–
102) in group 2 (p= 0.321).
Discussion
This study investigated the calculated blood loss and transfu-
sion rate after THA, using a short-stem design compared to a
straight-stem design. We found blood loss and transfusion
rates significantly lower in the short-stem group.
THA is reported to lead to substantial blood loss, which
often leads to blood transfusion [16, 17]. Due to the
demographic changes that will occur over the next century,
an increase in the total number of THAs can be expected;
therefore, the total number of blood transfusions will also
increase. National trends in blood transfusions in the US from
2000 to 2009 showed that the allogeneic blood transfusion
rate increased, the homologous blood transfusion rate de-
creased, and the overall transfusion rate remained stable [18].
Although blood transfusions in orthopaedic surgery are a
well-establishedmethod to treat peri- and post-operative anae-
mia, transfusions are not without risks for the patient, and they
also include increased hospital costs and long-term morbidity
and mortality [19]. Transfusion-related complications com-
prise systemic infection (HIV, hepatitis), and increased local
and general infections, due to transfusion-triggered
immunomodulation [20, 21]. Therefore, minimizing blood
loss, which subsequently lowers the transfusion rate, is of
fundamental importance to improve patient outcomes and to
lower complication rates and costs for the health system.
The transfusion rate in this study was 15.6% in group 2
(straight-stem) and 8% in group 1 (short-stem), which are both
lower than in most previously published studies [9, 10, 22,
23]. There is a wide variation of reported transfusion rates
after THA in the literature, ranging from 10 to 69% [9, 10,
22, 23]. In a prospective observational study of 114 THA, the
allogeneic transfusion rate was 18% [22]. In a study by Wong
et al. [24] the authors investigated 787 THA and found an
allogeneic transfusion rate of 23%. However, 36 surgeons
performed the surgeries, and no information about the implant
and surgical technique are mentioned, which makes compar-
ison to our results difficult.
n this study, the calculated blood loss was 1139 ml for
group 1 and 1358 ml for group 2. Blood loss after THA is
reported to be between approximately 600 and 1800 ml [6–8].
Post-operative haematocrit is reported to be lowest on the sec-
ond or third post-operative day [25, 26]. However, in group 1,
Table 2 Pre-operative and post-operative hematocrit (Hct) value.
Values are given as mean SD ±
Hct (%) Short-stem Straight-stem p
Pre-operative 41.9 ± 3.6 41.1 ± 3.6 0.17
Day 1 32.7 ± 4.1 32.8 ± 4.1 0.9
Day 3 36.3 ± 5.4 31.9 ± 5.4 <0.001
Table 3 Pre-operative and post-operative hemoglobin (Hb) value.
Values are given as mean SD ±
Hb (mg/dL) Short-stem Straight-stem p
Pre-operative 14.1 ± 1.3 13.8 ± 1.3 0.11
Day 1 11.1 ± 1.4 11.1 ± 1.4 0.87
Day 3 12.4 ± 1.9 10.7 ± 0.2 <0.001
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haemoglobin and haematocrit were higher on post-operative day
three, than on day one. Additionally, between the groups,
haemoglobin and haematocrit values were not significantly dif-
ferent on post-operative day one, but were significantly lower in
group 2 on post-operative day 3.
For us, this can be explained by a probably,
incorrect-low measured haematocrit and haemoglobin
value on post-operative day one for patients of group 1,
due to the dilution effect, caused by intra-operative fluid
administration.




Fig. 1 The haemoglobin levels
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Data for blood loss after joint replacement in the literature
are hardly comparable to each other due to the heterogeneity
of patients and the many different equations used to calculate
blood loss [27].
Amount of blood loss after joint replacement is determined
by multiple factors, such as body mass index, indication for
surgery, surgical approach, comorbidities, and anticoagulant
agents. Reported risk factors for blood transfusion are female
gender and lower pre-operative haemoglobin level [9, 24].
Several studies proved that blood loss and transfusion rates
can be reduced by antifibrinolytic agents and hospitals’ own
pre-operative programs [28, 29].
The use of tranexamic acid (TXA), or aminocaproic acid
have been shown to minimize blood loss in orthopaedic sur-
gery. The most widely used is TXA, of which, systemic ad-
ministration has been proven in many peer-reviewed studies
to lower peri-operative and post-operative blood transfusion
[30, 31]. In our institution, TXA has been routinely used since
June 2015. Therefore, for this study, none of the patients re-
ceived TXA in either of the groups.
Patients in both groups routinely received one intra-
articular closed-suction drain. However, there is some evi-
dence that closed-suction drains in THA increase blood trans-
fusion [32]. Johansson et al. [33] found in a prospective, ran-
domized controlled trial that wound compressions reduce
wound discharge, and transfusion rates compared to drainage
after THA. Therefore, not using drainage would have proba-
bly lowered blood loss and transfusion rates in both groups.
In a study by Chang-peng et al. [34], the authors showed
that compared to standard incision in THA, there is some
evidence that mini-incision reduces blood loss. However,
there is no clear definition of Bminimally invasive,^ and most
would agree that soft tissue trauma is determined, not by
length of incision but mainly by trauma to muscle tissue.
Undoubtedly, muscle and soft tissue damage during sur-
gery is one of the major bleeding sources in THA. The curved
and short femoral stem allows implantation without damaging
almost any gluteal muscle, and without damaging the major
trochanter. The stem can be brought in by sliding along the
medial calcar of the preserved femoral neck. We think that in
addition to muscle tissue, another major source of blood loss
in cement-less THA is the bone. In standard straight stems,
due to the straight stem design and the distal anchorage of the
stem, some degree of major trochanter damage is unavoidable
to obtain straight access to the intramedullary canal.
Additionally, the femoral canal has to be prepared far more
distally, which may also produce further blood loss.
Therefore, we feel straight stems may unavoidably cause
some more degree of muscle damage and bleeding.









Calculated blood loss (ml) 1139 ± 459 1358 ± 490 <0.001
Transfusions (mean number of
transfused packs per patient)
0.10 ± 0.4 0.34 ± 1.7 <0.001
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The limitations of this study are its retrospective design and
the small sample size of the groups and the different surgical
approaches used for the two groups. Despite the threshold of
7 mg/dl for transfusion, clinical symptoms, such as tachycar-
dia, hypotension, chest pain, fatigue, and the decision to trans-
fuse a patient, may be influenced subjectively, and may bias
the transfusion rate of the groups. Furthermore, the results of
this study are only applicable for cement-less THA. On the
other hand, all patients in both groups were operated on by the
same, highly experienced surgeon, and patient groups were
very similar, concerning demographic characteristics. In this
study, no patient received tranexamic (TXA) acid and no cell
savers were used. The routine use of TXA and cell savers may
have led to lower overall blood loss in both groups. However,
this did not affect comparison of the groups.
In summary, compared to patients after straight-stem THA,
blood loss and blood transfusion rates were lower, and post-
operative haemoglobin and haematocrit levels were higher, in
patients after short-stem THA. Of course, the findings can be
applicable only for cement-less THA and for the particular
designs used in the study groups. As there is no significant
difference in operation time and surgeon, we think that the
lower estimated blood loss in the short-stem patients is mainly
due to the minimized soft tissue trauma during surgery. The
curved design and the short length of the shaft allow a gentler
implantation without damaging the major trochanter and the
gluteal muscle.
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